研究概要
这些发现突出了TI-Treg细胞在不同肿瘤部位之间的异质性,以及荷瘤宿主中脾脏Treg细胞的独特性质。
中文摘要
在结直肠癌(CRC)中,肿瘤浸润性调节性T(Treg)细胞抑制抗肿瘤免疫,促进免疫逃逸和肿瘤进展。有效的治疗需要选择性靶向肿瘤浸润性Treg(TI-Treg)细胞,同时保留系统性Treg细胞,因此需要深入了解它们在肿瘤微环境中的适应性变化。在此,将CRC类器官植入Foxp3eGFP小鼠肝脏,以研究TI-Treg细胞的位置特异性表型差异。在我们的队列中,与匹配的健康组织相比,肿瘤组织表现出Treg细胞比例增加,效应CD4+和CD8+T细胞比例降低。对从脾脏、原发性肝肿瘤移植物或转移灶中分离的Treg细胞进行RNA测序,鉴定出先前与患者CRC相关Treg细胞相关的基因表达谱。位置特异性差异包括与肝脏对应细胞相比,腹膜TI-Treg细胞中WNT通路基因表达升高。肝脏TI-Treg细胞中上调基因的更高表达与CRC不良预后相关。荷瘤小鼠的脾脏Treg细胞显示出与其健康对应细胞和TI-Treg细胞均不同的转录谱,表明它们代表一个独特的CD4+群体。综上所述,这些发现突出了TI-Treg细胞在不同肿瘤部位之间的异质性,以及荷瘤宿主中脾脏Treg细胞的独特性质。
展开英文摘要原文
In colorectal cancer (CRC), tumor-infiltrating regulatory T (Treg) cells suppress anti-tumor immunity, promoting immune evasion and tumor progression. Effective therapies require selectively targeting tumor-infiltrating Treg (TI-Treg) cells while preserving systemic Treg cells, necessitating insight into their adaptations within the tumor microenvironment. Here, CRC-organoids were implanted in the liver of Foxp3eGFP mice to investigate location-specific phenotypic differences in TI-Treg cells. In our cohort, tumor tissue exhibited an increased proportion of Treg cells and a decrease proportion of effector CD4 + and CD8 + T cells compared to matched healthy tissue. RNA sequencing of Treg cells isolated from the spleen, primary liver tumor transplant, or metastases identified gene expression profiles previously associated with CRC-related Treg cells in patients. Location-specific differences included elevated expression of WNT-pathway genes in peritoneal TI-Treg cells compared to liver counterparts. Higher expression of genes upregulated in liver TI-Treg cells correlated with poor CRC prognosis. Splenic Treg cells from tumor-bearing mice displayed distinct transcriptional profiles from both their healthy counterparts and TI-Treg cells, suggesting they represent a distinct CD4 + population. Taken together, these findings highlight TI-Treg cells heterogeneity across different tumor sites and the distinct nature of splenic Treg cells in tumor-bearing hosts.
论文信息
- 作者
- Aristin Revilla S、Verheem A、Frederiks CL、Kim Y、Chalkiadakis T、Viergever BJ、Győrffy B、Mocholi E
- 第一作者单位
- Center Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, the Netherlands; Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.Netherlands
- 通讯作者单位
- Center Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: pcoffer@umcutrecht.nl.Netherlands
- 期刊
- Cancer letters2026 Sep 28